Navigated micropulse laser for central serous chorioretinopathy: Efficacy, safety, and predictive factors of treatment response
| Autor: | Oudy Semoun, Salomon Y. Cohen, D. Colantuono, Jay Chhablani, Vittorio Capuano, Camille Jung, Alexandra Miere, Alexandre Pedinielli, Eric H. Souied, Francesca Amoroso, Polina Astroz |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Indocyanine Green
Male Treatment response medicine.medical_specialty Visual acuity Visual Acuity Chronic central serous chorioretinopathy law.invention law Ophthalmology Humans Medicine Fluorescein Angiography Adverse effect Retrospective Studies medicine.diagnostic_test business.industry Lasers Laser treatment General Medicine Middle Aged Laser Fluorescein angiography Serous fluid Treatment Outcome Central Serous Chorioretinopathy Photochemotherapy Chronic Disease Female medicine.symptom business Tomography Optical Coherence |
| Zdroj: | European Journal of Ophthalmology. 32:2810-2818 |
| ISSN: | 1724-6016 1120-6721 |
| DOI: | 10.1177/11206721211064021 |
| Popis: | Purpose There is no widely accepted treatment for persistent/chronic central serous chorioretinopathy. The present study aimed to evaluate the efficacy, safety, and factors associated to treatment response to navigated micropulse laser in chorioretinopathy. Methods Retrospective observational case series including consecutive patients presenting with symptomatic persistent and chronic chorioretinopathy. All patients were treated with 5% navigated micropulse laser with the Navilas system (Navilas®, OD-OS GmBH, Teltwo, Germany), by overlying fluorescein angiography, indocyanine green angiography and/or spectral domain-optical coherence tomography images of visible leaking points and/or choroidal hyperpermeability/subretinal fluid to plan the laser treatment. Results Thirty-nine eyes of 36 consecutive patients (29 men and 7 women, with a mean age of 51.87 years) were included. Logarithm of the minimum angle of resolution (LogMar) best-corrected visual acuity increased from 0.39 ± 0.24 at baseline to 0.24 ± 0.22 at 3 months ( p Conclusion Navigated micropulse laser laser treatment was found to be effective and safe for the treatment of chorioretinopathy, with significant improvement in visual and anatomical outcomes, unaccompanied by any adverse event at 3 and 6 months follow-up. Factors associated to subretinal fluid resolution may allow a better selection of likely responders to navigated micropulse laser treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|